ICU Medical, Incorporated (ICUI) Expected to Post Earnings of $1.47 Per Share

Wall Street analysts expect that ICU Medical, Incorporated (NASDAQ:ICUI) will report earnings of $1.47 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for ICU Medical’s earnings, with the highest EPS estimate coming in at $1.61 and the lowest estimate coming in at $1.32. ICU Medical posted earnings of $1.12 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 31.3%. The firm is expected to announce its next earnings report on Thursday, November 8th.

On average, analysts expect that ICU Medical will report full-year earnings of $8.48 per share for the current year, with EPS estimates ranging from $8.35 to $8.60. For the next financial year, analysts forecast that the firm will post earnings of $9.95 per share, with EPS estimates ranging from $9.87 to $10.03. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover ICU Medical.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, August 9th. The medical instruments supplier reported $2.66 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.82 by $0.84. ICU Medical had a return on equity of 12.78% and a net margin of 5.93%. The business had revenue of $360.46 million during the quarter, compared to analysts’ expectations of $337.60 million. During the same period in the previous year, the firm posted $0.76 earnings per share. The company’s revenue was up 8.7% on a year-over-year basis.

A number of brokerages have recently weighed in on ICUI. TheStreet raised ICU Medical from a “c+” rating to a “b+” rating in a research note on Monday, August 20th. Zacks Investment Research raised ICU Medical from a “hold” rating to a “strong-buy” rating and set a $337.00 target price for the company in a research note on Wednesday, August 15th. Finally, ValuEngine raised ICU Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 2nd. One analyst has rated the stock with a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Strong Buy” and an average price target of $337.00.

In related news, VP Alison D. Burcar sold 21,311 shares of the business’s stock in a transaction on Monday, June 18th. The stock was sold at an average price of $302.82, for a total transaction of $6,453,397.02. Following the completion of the transaction, the vice president now directly owns 21,311 shares of the company’s stock, valued at approximately $6,453,397.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Pfizer Inc sold 700,000 shares of the business’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $284.35, for a total value of $199,045,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 888,614 shares of company stock valued at $255,217,663 over the last three months. 12.50% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Zeke Capital Advisors LLC purchased a new stake in ICU Medical during the 1st quarter worth about $200,000. Mackay Shields LLC purchased a new stake in shares of ICU Medical in the 2nd quarter valued at about $205,000. Eagle Boston Investment Management Inc. purchased a new stake in shares of ICU Medical in the 1st quarter valued at about $206,000. CIBC Asset Management Inc purchased a new stake in shares of ICU Medical in the 2nd quarter valued at about $209,000. Finally, LPL Financial LLC purchased a new stake in shares of ICU Medical in the 1st quarter valued at about $218,000. 74.29% of the stock is owned by institutional investors.

Shares of NASDAQ ICUI traded up $1.50 during trading on Monday, reaching $305.50. The stock had a trading volume of 180,700 shares, compared to its average volume of 147,569. ICU Medical has a fifty-two week low of $169.07 and a fifty-two week high of $321.70. The stock has a market capitalization of $6.22 billion, a PE ratio of 55.34 and a beta of 0.36.

About ICU Medical

ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.

Featured Story: Asset Allocation

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply